Literature DB >> 30410218

Ribociclib for breast cancer.

.   

Abstract

Entities:  

Year:  2018        PMID: 30410218      PMCID: PMC6202289          DOI: 10.18773/austprescr.2018.058

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


× No keyword cloud information.
  2 in total

1.  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Authors:  G N Hortobagyi; S M Stemmer; H A Burris; Y S Yap; G S Sonke; S Paluch-Shimon; M Campone; K Petrakova; K L Blackwell; E P Winer; W Janni; S Verma; P Conte; C L Arteaga; D A Cameron; S Mondal; F Su; M Miller; M Elmeliegy; C Germa; J O'Shaughnessy
Journal:  Ann Oncol       Date:  2018-07-01       Impact factor: 32.976

2.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Authors:  Gabriel N Hortobagyi; Salomon M Stemmer; Howard A Burris; Yoon-Sim Yap; Gabe S Sonke; Shani Paluch-Shimon; Mario Campone; Kimberly L Blackwell; Fabrice André; Eric P Winer; Wolfgang Janni; Sunil Verma; Pierfranco Conte; Carlos L Arteaga; David A Cameron; Katarina Petrakova; Lowell L Hart; Cristian Villanueva; Arlene Chan; Erik Jakobsen; Arnd Nusch; Olga Burdaeva; Eva-Maria Grischke; Emilio Alba; Erik Wist; Norbert Marschner; Anne M Favret; Denise Yardley; Thomas Bachelot; Ling-Ming Tseng; Sibel Blau; Fengjuan Xuan; Farida Souami; Michelle Miller; Caroline Germa; Samit Hirawat; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

  2 in total
  1 in total

Review 1.  Interactions between cardiology and oncology drugs in precision cardio-oncology.

Authors:  Sailaja Kamaraju; Meera Mohan; Svetlana Zaharova; Brianna Wallace; Joseph McGraw; James Lokken; John Tierney; Elizabeth Weil; Olubadewa Fatunde; Sherry-Ann Brown
Journal:  Clin Sci (Lond)       Date:  2021-06-11       Impact factor: 6.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.